Stock Analysis

Nolato Full Year 2023 Earnings: Misses Expectations

OM:NOLA B
Source: Shutterstock

Nolato (STO:NOLA B) Full Year 2023 Results

Key Financial Results

  • Revenue: kr9.55b (down 11% from FY 2022).
  • Net income: kr435.0m (down 38% from FY 2022).
  • Profit margin: 4.6% (down from 6.5% in FY 2022). The decrease in margin was driven by lower revenue.
  • EPS: kr1.62 (down from kr2.59 in FY 2022).
revenue-and-expenses-breakdown
OM:NOLA B Revenue and Expenses Breakdown April 15th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nolato Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 13%.

The primary driver behind last 12 months revenue was the Medical Solutions segment contributing a total revenue of kr5.31b (56% of total revenue). Notably, cost of sales worth kr8.21b amounted to 86% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to kr467.0m (52% of total expenses). Explore how NOLA B's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Industrials industry in Sweden.

Performance of the Swedish Industrials industry.

The company's shares are down 1.2% from a week ago.

Risk Analysis

Be aware that Nolato is showing 1 warning sign in our investment analysis that you should know about...

Valuation is complex, but we're helping make it simple.

Find out whether Nolato is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St

Simply Wall St

About OM:NOLA B

Nolato

Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products for medical technology, pharmaceutical, consumer electronics, telecom, automotive, hygiene, and other industrial sectors in Sweden, Other Nordic countries, Asia, Rest of Europe, and North America, and internationally.

Excellent balance sheet with reasonable growth potential.